$WCUI
Wellness Center USA, Inc. Stock $wcui

$wcui Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000149315222022819 Filed on August 15, 2022

Income Statement

Concept	2022 Q2	2021 Q3	2021 Q2
Revenue	$107.5K	$19.19K	$78.62K
YoY Change	36.73%
Cost Of Revenue	$10.40K	$79.13K	$10.40K
YoY Change	0.0%
Gross Profit	$97.10K	-$59.94K	$68.22K
YoY Change	42.33%
Gross Profit Margin	90.33%	-312.35%	86.77%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$0.00	$0.00
YoY Change
% of Gross Profit			0.0%
Operating Expenses	$430.2K	$295.8K	$272.7K
YoY Change	57.79%	-16.15%	-66.48%
Operating Profit	-$333.1K	-$355.8K	-$204.4K
YoY Change	62.94%	0.84%	-74.86%
Interest Expense	-$408.5K	-$40.07K	-$36.23K
YoY Change	1027.63%	77.46%	-43.01%
% of Operating Profit
Other Income/Expense, Net	-$408.5K	-$1.680K	-$36.23K
YoY Change	1027.63%		59.74%
Pretax Income	-$741.7K	-$360.3K	-$240.7K
YoY Change	208.16%	13.12%	-73.13%
Income Tax
% Of Pretax Income
Net Earnings	-$622.1K	-$258.8K	-$153.6K
YoY Change	305.03%	63.79%	-81.25%
Net Earnings / Revenue	-578.72%	-1348.57%	-195.37%
Basic Earnings Per Share	-$0.01		$0.00
Diluted Earnings Per Share	-$4.601K	-$2.104K	-$1.258K
COMMON SHARES
Basic Shares Outstanding	135.2M shares		122.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q2	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.05K	$32.08K	$41.80K
YoY Change	0.6%	-37.49%	-55.68%
Cash & Equivalents	$42.05K	$32.08K	$41.80K
Short-Term Investments
Other Short-Term Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Inventory	$99.74K	$50.00K	$129.1K
Prepaid Expenses
Receivables			$37.50K
Other Receivables			$0.00
Total Short-Term Assets	$141.8K	$82.08K	$208.4K
YoY Change	-31.97%	-43.93%	21.26%
LONG-TERM ASSETS
Property, Plant & Equipment		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$141.8K	$82.08K	$208.4K
Total Long-Term Assets	$0.00
Total Assets	$141.8K	$82.08K	$208.4K
YoY Change	-31.97%	-46.47%	13.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$716.0K	$624.3K	$549.1K
YoY Change	30.4%	52.91%	14.49%
Accrued Expenses	$610.2K	$748.7K	$753.2K
YoY Change	-18.99%	-3.04%	-3.68%
Deferred Revenue
YoY Change
Short-Term Debt	$2.510M	$2.055M	$1.916M
YoY Change	30.96%	76.39%	81.76%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.836M	$3.428M	$3.219M
YoY Change	19.18%	46.16%	38.98%
LONG-TERM LIABILITIES
Long-Term Debt	$304.6K	$0.00	$37.17K
YoY Change	719.48%	-100.0%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$304.6K	$0.00	$37.17K
YoY Change	719.48%	-100.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.836M	$3.428M	$3.219M
Total Long-Term Liabilities	$304.6K	$0.00	$37.17K
Total Liabilities	$4.140M	$3.428M	$3.019M
YoY Change	37.16%	33.67%	13.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.32M	-$28.39M
YoY Change
Common Stock	$25.93M	$25.38M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.390M	-$3.008M	-$2.810M
YoY Change
Total Liabilities & Shareholders Equity	$141.8K	$82.08K	$208.4K
YoY Change	-31.97%	-46.47%	13.18%

Cashflow Statement

Concept	2022 Q2	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$622.1K	-$258.8K	-$153.6K
YoY Change	305.03%	63.79%	-81.25%
Depreciation, Depletion And Amortization		$0.00	$0.00
YoY Change
Cash From Operating Activities	-$297.4K	-$164.7K	-$195.3K
YoY Change	52.26%	-39.9%	-1.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	275.0K	155.0K	91.00K
YoY Change	202.2%	-32.92%	-63.91%
NET CHANGE
Cash From Operating Activities	-297.4K	-164.7K	-195.3K
Cash From Investing Activities
Cash From Financing Activities	275.0K	155.0K	91.00K
Net Change In Cash	-22.43K	-9.720K	-104.3K
YoY Change	-78.5%	-77.39%	-292.62%
FREE CASH FLOW
Cash From Operating Activities	-$297.4K	-$164.7K	-$195.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001516887
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	WCUI	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	WCUI	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2021Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	WCUI	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodExercisePrice
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021Q2	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	WCUI	Fair Value Of Common Stock Issued In Connection With Shareholder Loans FairValueOfCommonStockIssuedInConnectionWithShareholderLoans		usd
	WCUI	Fair Value Of Common Stock Issued For Consulting Services FairValueOfCommonStockIssuedForConsultingServices		usd
	WCUI	Fair Value Of Stock Options Issued For Services FairValueOfStockOptionsIssuedForServices		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets		usd
	WCUI	Increase Decrease In Operating Lease Abandonment Liability IncreaseDecreaseInOperatingLeaseAbandonmentLiability		usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
	WCUI	Proceeds From Small Business Administration Loan Payable ProceedsFromSmallBusinessAdministrationLoanPayable		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	WCUI	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2022Q2	WCUI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedExercisePrice
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	WELLNESS CENTER USA, INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity File Number EntityFileNumber	333-173216
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2980395
	dei	Entity Address Address Line1 EntityAddressAddressLine1	145 E. University Boulevard
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tucson
	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85705
	dei	City Area Code CityAreaCode	(847)
	dei	Local Phone Number LocalPhoneNumber	925-1885
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135999577	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42045	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32079	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	99741	usd
CY2021Q3	us-gaap	Inventory Net InventoryNet	50000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	141786	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	82079	usd
CY2022Q2	us-gaap	Assets Assets	141786	usd
CY2021Q3	us-gaap	Assets Assets	82079	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	716008	usd
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	624337	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	62334	usd
CY2021Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	75834	usd
CY2022Q2	WCUI	Lease Abandonment Liability LeaseAbandonmentLiability	547878	usd
CY2021Q3	WCUI	Lease Abandonment Liability LeaseAbandonmentLiability	672878	usd
CY2022Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	1907250	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2697	usd
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	15822	usd
CY2022Q2	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	2509503	usd
CY2021Q3	us-gaap	Due To Officers Or Stockholders Current DueToOfficersOrStockholdersCurrent	2055378	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3835723	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3428427	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	304600	usd
CY2022Q2	us-gaap	Liabilities Liabilities	4140323	usd
CY2021Q3	us-gaap	Liabilities Liabilities	3428427	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135999577	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135999577	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123877077	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123877077	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	136000	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	123877	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	25795757	usd
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	25258005	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29321882	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28389628	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3390125	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-3007746	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-608412	usd
CY2021Q3	us-gaap	Minority Interest MinorityInterest	-338602	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3998537	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3346348	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141786	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82079	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	107500	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	78620	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	372042	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	220769	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10400	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10400	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	46800	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	149450	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	97100	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	68220	usd
	us-gaap	Gross Profit GrossProfit	325242	usd
	us-gaap	Gross Profit GrossProfit	71319	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	430227	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	272666	usd
	us-gaap	Operating Expenses OperatingExpenses	1028678	usd
	us-gaap	Operating Expenses OperatingExpenses	943425	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-333127	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-204446	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-703436	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-872106	usd
CY2022Q2	us-gaap	Interest Expense Other InterestExpenseOther	51166	usd
CY2021Q2	us-gaap	Interest Expense Other InterestExpenseOther	36230	usd
	us-gaap	Interest Expense Other InterestExpenseOther	137417	usd
	us-gaap	Interest Expense Other InterestExpenseOther	94381	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4375	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13125	usd
CY2022Q2	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-353000	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	-353000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4914	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-408541	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36230	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-498628	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-94381	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-741668	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-240676	usd
	us-gaap	Profit Loss ProfitLoss	-1202064	usd
	us-gaap	Profit Loss ProfitLoss	-966487	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-119547	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-87079	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-269810	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-419015	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-622121	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-153597	usd
	us-gaap	Net Income Loss NetIncomeLoss	-932254	usd
	us-gaap	Net Income Loss NetIncomeLoss	-547472	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135226912	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	122096521	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128602434	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	120257205	shares
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3719244	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	59375	usd
CY2022Q2	WCUI	Fair Value Of Common Stock Issued To Officers And Directors In Connection With Shareholder Loans FairValueOfCommonStockIssuedToOfficersAndDirectorsInConnectionWithShareholderLoans	353000	usd
CY2022Q2	WCUI	Fair Value Of Common Stock Issued For Services To Consultants FairValueOfCommonStockIssuedForServicesToConsultants	50000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-741668	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3998537	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3346348	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	146875	usd
	WCUI	Fair Value Of Common Stock Issued To Officers And Directors In Connection With Shareholder Loans FairValueOfCommonStockIssuedToOfficersAndDirectorsInConnectionWithShareholderLoans	353000	usd
	WCUI	Fair Value Of Common Stock Issued For Services To Consultants FairValueOfCommonStockIssuedForServicesToConsultants	50000	usd
	us-gaap	Profit Loss ProfitLoss	-1202064	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3998537	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2850342	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	43750	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-240676	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3047268	usd
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2229545	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	21764	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	127000	usd
	us-gaap	Profit Loss ProfitLoss	-966487	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3047268	usd
	us-gaap	Profit Loss ProfitLoss	-1202064	usd
	us-gaap	Profit Loss ProfitLoss	-966487	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-760521	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	601000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	751000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	160000	usd
	WCUI	Proceeds From Small Business Administration Loan Payable ProceedsFromSmallBusinessAdministrationLoanPayable	304600	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	745600	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	751000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6961	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13125	usd
	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	146875	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	127000	usd
	WCUI	Fair Value Of Common Stock Issued In Connection With Shareholder Loans FairValueOfCommonStockIssuedInConnectionWithShareholderLoans	353000	usd
	WCUI	Fair Value Of Common Stock Issued For Consulting Services FairValueOfCommonStockIssuedForConsultingServices	50000	usd
	WCUI	Fair Value Of Stock Options Issued For Services FairValueOfStockOptionsIssuedForServices	21764	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4914	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37500	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	49741	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	134570	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-500	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	96585	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	140772	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-13500	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-12000	usd
	WCUI	Increase Decrease In Operating Lease Abandonment Liability IncreaseDecreaseInOperatingLeaseAbandonmentLiability	125000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6961	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-735634	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9966	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9521	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32079	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51320	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42045	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41799	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80F_eus-gaap--BasisOfAccounting_zGuSgs4G74bg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82D_zUIyuPlqgmOa">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization and Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in the following business segments: (i) distribution of targeted Ultraviolet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation of Unaudited Financial Information</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19 Considerations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended June 30, 2022, the COVID-19 pandemic did not have a material net impact on our operating results. In the future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the customers who purchase our products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the onset of the COVID-19 pandemic, we maintained the consistency of our operations. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through June 30, 2022, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date. Through June 30, 2022, the Company continues to generate cash flows through financing activities to meet its short-term liquidity needs, and it expects to maintain access to those shareholder loans. The Company has not observed any material impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the nine months ended June 30, 2022, the Company incurred a net loss of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ProfitLoss_iN_pp0p0_di_c20211001__20220630_zGRFzyG45xTa" title="Net loss">1,202,064</span> <span style="background-color: white">and used cash in operations of $</span><span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20211001__20220630_zh5OxO920tEe" title="Cash used in operations">735,634</span><span style="background-color: white">, and <span style="background-color: white">at June 30, 2022, </span> had a shareholders’ deficit of $</span><span id="xdx_90B_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iNI_pp0p0_di_c20220630_zB26l9LudxR1" title="Shareholders' deficit">3,998,537</span> <span style="background-color: white">as of June 30, 2022. In addition, loans payable of $</span><span id="xdx_90D_eus-gaap--LoansPayable_iI_pp0p0_c20220630_zfTzvClJOCh2" title="Loans payable">1,907,250</span> <span style="background-color: white">and payroll taxes of $</span><span id="xdx_90F_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_c20220630_z2VR9Z5nROAh" title="Payroll taxes due">62,334</span> <span style="background-color: white">are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report published on our September 30, 2021 year-end financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At June 30, 2022, the Company had cash on hand in the amount of $<span id="xdx_908_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20220630_zS5zBzRAIAM3" title="Cash on hand">42,045</span>. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the nine months ended June 30, 2022, the Company received $<span id="xdx_905_eus-gaap--ProceedsFromShortTermDebt_pp0p0_c20211001__20220630_zOJWWIgzBs1k" title="Short-term lonas from officers">601,000</span> through short-term loans from officers and shareholders and $<span id="xdx_90C_eus-gaap--LongTermLoansPayable_iI_c20220630_z4PWB1jSVEhe" title="Loan payable">304,600</span> through a U.S. SBA loan payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Profit Loss ProfitLoss	-1202064	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-735634	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3998537	usd
CY2022Q2	us-gaap	Loans Payable LoansPayable	1907250	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	62334	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42045	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	601000	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	304600	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zW83wMIqg4Mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zOLuqNLTX9ok">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2021Q3	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2021Q2	us-gaap	Inventory Adjustments InventoryAdjustments	173930	usd
CY2021Q3	us-gaap	Inventory Adjustments InventoryAdjustments	173930	usd
CY2021Q3	us-gaap	Due From Officers Or Stockholders DueFromOfficersOrStockholders	2071200	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	160000	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2512200	usd
CY2022Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	1907250	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	363530	usd
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	15822	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4375	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13125	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2697	usd
CY2022Q2	us-gaap	Due From Related Parties DueFromRelatedParties	304600	usd
CY2022Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0375	pure
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1569	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	304600	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	3974	usd
	WCUI	Lease Monthly Rental Payments LeaseMonthlyRentalPayments	11000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	631587	usd
CY2021Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	672878	usd
	us-gaap	Lease Cost LeaseCost	125000	usd
CY2022Q2	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	547878	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	8750000	shares
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	325000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3750000	shares
	WCUI	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted	187500	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	4062500	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	146875	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.04
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	8437500	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	365625	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.04
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3750000	shares
CY2022Q2	WCUI	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted	187500	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1250000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5277738	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	850000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.17
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4427738	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.14
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4427738	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.14
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42045	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	99741	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	141786	usd
CY2022Q2	us-gaap	Assets Assets	141786	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	107500	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10400	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	97100	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	430227	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-333127	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	78620	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10400	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	68220	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	272666	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-204446	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	372042	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	46800	usd
	us-gaap	Gross Profit GrossProfit	325242	usd
	us-gaap	Operating Expenses OperatingExpenses	1028678	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-703436	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	220769	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	149450	usd
	us-gaap	Gross Profit GrossProfit	71319	usd
	us-gaap	Operating Expenses OperatingExpenses	943425	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-872106	usd
CY2021Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	41914	usd
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	37000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	4914	usd

Files In Submission

Name	View Source	Status
0001493152-22-022819-index-headers.html	Edgar Link	pending
0001493152-22-022819-index.html	Edgar Link	pending
0001493152-22-022819.txt	Edgar Link	pending
0001493152-22-022819-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wcui-20220630.xsd	Edgar Link	pending
wcui-20220630_cal.xml	Edgar Link	unprocessable
wcui-20220630_def.xml	Edgar Link	unprocessable
wcui-20220630_lab.xml	Edgar Link	unprocessable
wcui-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WCUI
Wellness Center USA, Inc. Stock $wcui

2022 Q2 Form 10-Q Financial Statement

#000149315222022819 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WCUI Wellness Center USA, Inc. Stock $wcui

2022 Q2 Form 10-Q Financial Statement

#000149315222022819 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WCUI
Wellness Center USA, Inc. Stock $wcui